ClinicalTrials.gg
Active, not recruitingNCT06256328Updated Mar 13, 2026

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

A Phase 2 interventional study of ONO-4578 and Oxaliplatin in Gastric Cancer, sponsored by Ono Pharmaceutical Co., Ltd.. Active, not recruiting at 63 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 181 studies in Stomach Neoplasms with a site in Japan — 33 open to participants now, 55 under way, 12 of them phase 3. Stomach Neoplasms · Japan.

Enrollment
69th of 162
226 · median 158
Started
2024
with 6 others
Phase 2
40 of 181
9 open now
Primary completion
2025-10
later than 7 of 54 live
Registered
155th of 181
by date

Among the 181 studies in Stomach Neoplasms with a site in Japan, this one is the 69th largest by enrollment of the 162 interventional ones that give a count, is one of 7 that started in 2024, is one of 40 in phase 2, reaches primary completion later than 7 of the 54 other live ones, and was the 155th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

33 of the 181 studies in Stomach Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Stomach Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

This study is to compare and evaluate the efficacy and safety of the treatment with ONO-4578 in combination with nivolumab and chemotherapy with those of the treatment with placebo in combination with nivolumab and chemotherapy in chemotherapy-naïve participants with HER2- negative unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer).

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with gastric or esophagogastric junction cancer diagnosed as adenocarcinoma
  • Patients have not been treated with systemic chemotherapy as therapy
  • Patients who can provide tumor tissue samples

Exclusion criteria

Exclusion Criteria:

  • Patients unable to take oral medicines
  • Patients with -positive
  • Patients with to nivolumab, oxaliplatin, S-1, or capecitabine
  • Patients who have a history of severe drug-related adverse reactions caused by non- steroidal anti-inflammatory drugs (NSAIDs) or who have complications caused by NSAIDs requiring treatment
  • Patients with concurrent disease or a history of chronic or recurrent autoimmune disease, such as rheumatoid arthritis
  • Patients with headache and/or nausea associated with
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    ONO-4578+Nivolumab+chemotherapy

    Drug: ONO-4578 · Drug: Oxaliplatin · Drug: Capecitabine · Drug: S-1 · Drug: Nivolumab

  • Placebo comparator
    placebo+Nivolumab+chemotherapy

    Drug: Oxaliplatin · Drug: Capecitabine · Drug: S-1 · Drug: Nivolumab · Drug: Placebo

Interventions

  • Specified dose, once daily

  • Specified dose on specified days

  • Specified dose on specified days

  • DrugS-1

    Drug pages: Tegafur · Gimeracil · Oxonic Acid

    Specified dose on specified days

    Also known as: Tegafur-gimeracil-oteracil potassium

  • Specified dose on specified days

    Also known as: Opdivo

  • DrugPlacebo

    Specified dose, once daily

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) (site investigator assessment)

    Time frame: up to 2years

Secondary outcomes

  1. Overall survival (OS)

    Time frame: up to 2years

  2. Objective response rate (ORR) (site investigator assessment)

    Time frame: up to 2years

  3. Best overall response (BOR) (site investigator assessment)

    Time frame: up to 2years

  4. Duration of response (DOR) (site investigator assessment)

    Time frame: up to 2years

  5. Disease control rate (DCR) (site investigator assessment)

    Time frame: up to 2years

  6. Time to response (TTR) (site investigator assessment)

    Time frame: up to 2years

  7. Maximum percent change in the sum diameters of the target lesions (site investigator assessment)

    Time frame: up to 2years

  8. Progression-free survival after the next line of therapy (PFS2) (site investigator assessment)

    Time frame: up to 2years

  9. Adverse event (AE)

    Number of participants with treatment-emergent adverse events (TEAEs) as assessed by CTCAE v5.0

    Time frame: Up to 30 days after the last dose

07

Study locations

63 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Oct 2025, 20 months.

Of 65 industry-sponsored phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 68. This study's 20 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2024
First posted
Feb 13, 2024
StartActual
Jan 10, 2024
Primary completionActual
Oct 9, 2025
CompletionEst.
Jul 31, 2027
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06256328
Responsible party
Sponsor
First posted
Feb 13, 2024
Start date
Jan 10, 2024
Primary completion
Oct 9, 2025
Completion
Jul 31, 2027 (estimated)
Last update
Mar 13, 2026

Study contacts

Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BMS-986310

Start the discussion